Why should we monitor for hematologic adverse drug reactions to oxcarbazepine?
作者信息
Jang Gwang Cheon
机构信息
Department of Pediatrics, National Health Insurance Service Ilsan Hospital, Goyang, Korea.
出版信息
Korean J Pediatr. 2019 Aug;62(8):299-300. doi: 10.3345/kjp.2019.00472. Epub 2019 Jun 24.
Abstract
摘要
相似文献
1
Why should we monitor for hematologic adverse drug reactions to oxcarbazepine?为什么我们要监测奥卡西平的血液学药物不良反应？
Korean J Pediatr. 2019 Aug;62(8):299-300. doi: 10.3345/kjp.2019.00472. Epub 2019 Jun 24.
2
Desensitization to Oxcarbazepine: Long-Term Efficacy and Tolerability.奥卡西平脱敏治疗：长期疗效与耐受性
J Clin Neurol. 2017 Jan;13(1):47-54. doi: 10.3988/jcn.2017.13.1.47. Epub 2016 Oct 7.
3
Oxcarbazepine: an update of its efficacy in the management of epilepsy.奥卡西平：其在癫痫治疗中疗效的最新进展
CNS Drugs. 2001;15(2):137-63. doi: 10.2165/00023210-200115020-00005.
4
[Adverse effects of oxcarbazepine].[奥卡西平的不良反应]
Zhongguo Dang Dai Er Ke Za Zhi. 2015 Apr;17(4):414-9.
5
and Oxcarbazepine-Induced DRESS in a Patient With Seizures and Complete Deletion.奥卡西平诱导的一名伴有癫痫发作和完全缺失患者的 DRESS 反应。
Pediatrics. 2018 Apr;141(Suppl 5):S434-S438. doi: 10.1542/peds.2017-1361.
6
Oxcarbazepine, an antiepileptic agent.奥卡西平，一种抗癫痫药。
Clin Ther. 2001 May;23(5):680-700; discussion 645. doi: 10.1016/s0149-2918(01)80019-9.
7
Association between HLA-B*15:02 and oxcarbazepine-induced cutaneous adverse reaction: a meta-analysis.HLA - B*15:02与奥卡西平诱导的皮肤不良反应之间的关联：一项荟萃分析。
Pharmacogenomics. 2018 Apr;19(6):547-552. doi: 10.2217/pgs-2017-0189. Epub 2018 Apr 9.
8
Oxcarbazepine for trigeminal neuralgia may induce lower extremity weakness: A case report.卡马西平治疗三叉神经痛可能诱发下肢无力：一例报告。 （注：原文中“Oxcarbazepine”有误，正确的是“Carbamazepine”，译文按正确药物名翻译）
World J Clin Cases. 2020 Mar 6;8(5):922-927. doi: 10.12998/wjcc.v8.i5.922.
9
Oxcarbazepine: new preparation. An alternative to carbamazepine in partial epilepsy.奥卡西平：新制剂。部分性癫痫中卡马西平的替代药物。
Prescrire Int. 2001 Dec;10(56):170-4.
10
Oxcarbazepine, topiramate, zonisamide, and levetiracetam: potential use in neuropathic pain.奥卡西平、托吡酯、唑尼沙胺和左乙拉西坦：在神经性疼痛中的潜在用途。
Am J Geriatr Pharmacother. 2003 Sep;1(1):18-37. doi: 10.1016/s1543-5946(03)80013-2.
本文引用的文献
1
Evaluation of hematologic profile may be needed for patients treated with oxcarbazepine.接受奥卡西平治疗的患者可能需要评估血液学指标。
Korean J Pediatr. 2019 Aug;62(8):312-316. doi: 10.3345/kjp.2019.00017. Epub 2019 Apr 11.
2
Risk and association of HLA with oxcarbazepine-induced cutaneous adverse reactions in Asians.亚洲人群中 HLA 与奥卡西平诱发的皮肤不良反应的风险及相关性
Neurology. 2017 Jan 3;88(1):78-86. doi: 10.1212/WNL.0000000000003453. Epub 2016 Dec 2.
3
HLA-B*40:02 and DRB1*04:03 are risk factors for oxcarbazepine-induced maculopapular eruption.HLA - B*40:02和DRB1*04:03是奥卡西平诱发斑丘疹的危险因素。
Epilepsia. 2016 Nov;57(11):1879-1886. doi: 10.1111/epi.13566. Epub 2016 Sep 26.
4
Anticonvulsant drugs and hematological disease.抗癫痫药物与血液系统疾病。
Neurol Sci. 2014 Jul;35(7):983-93. doi: 10.1007/s10072-014-1701-0. Epub 2014 Mar 12.
5
Pancytopenia associated with the introduction of oxcarbazepine.与奥卡西平引入相关的全血细胞减少症。
J Clin Psychopharmacol. 2007 Apr;27(2):217-8. doi: 10.1097/01.jcp.0000264971.92828.b2.
6
Oxcarbazepine-induced thrombocytopenia.奥卡西平所致血小板减少症。
Psychosomatics. 2006 Jan-Feb;47(1):73-4. doi: 10.1176/appi.psy.47.1.73.
7
Epidemiology of hypersensitivity drug reactions.药物超敏反应的流行病学
Curr Opin Allergy Clin Immunol. 2005 Aug;5(4):309-16. doi: 10.1097/01.all.0000173785.81024.33.
8
Oxcarbazepine.奥卡西平
Epilepsia. 1999;40 Suppl 5:S37-46. doi: 10.1111/j.1528-1157.1999.tb00918.x.
Zotero 插件